Kythera Doubles Down On Double Chins With Bayer Buyback
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech buys back rights to its own drug after attaining a more advantageous financial position and successful late-stage results.
You may also be interested in...
Kythera Faces Advisory Committee Meeting For Double Chin Drug
The California biotech faces one last hurdle before potential approval of its double chin injectable ATX-101 when it comes in front of the FDA’s dermatology advisory committee.
Deals Of The Week Looks At 2014 Takeout Targets
The hot field of immuno-oncology once again dominated the deal landscape with tie-ups between Bristol and Five Prime, Tesaro and AntaptysBio, and Medimmune and MD Anderson. Kythera and Bayer parted ways while Sanofi Pasteur teamed up with SK Chemicals.
Kythera Readies NDA For Double Chin Drug ATX-101
The specialty pharma is preparing a new drug application for its lead product candidate, hoping the demand for drugs like wrinkle-reducing toxins will translate to the submental fat market.